{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:53:51Z","timestamp":1792184031209,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/ppo.0b013e3181594774","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T08:36:50Z","timestamp":1209890210000},"page":"372-376","source":"Crossref","is-referenced-by-count":7,"title":["Expertise-Based Management in Essential Thrombocythemia and Polycythemia Vera"],"prefix":"10.1097","volume":"13","author":[{"given":"Guido","family":"Finazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat patients with polycythemia vera.","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"key":"R2-6-20210203","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Morbidity and mortality of a multicountry prospective cohort of 1,638 patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-6-20210203","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired vonWillebrand disease in patients with high platelet counts.","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status.","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","article-title":"Essential thrombocythaemia: challenges and evidence-based management.","volume":"130","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia.","volume":"132","author":"Cheung","year":"2005","journal-title":"Br J Haematol"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation.","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden.","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance.","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"R18-6-20210203","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk essential thrombocythemia: results from a prospective study.","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The hematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"R26-6-20210203","first-page":"17","article-title":"From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera.","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1,638 patients enrolled in a prospective observational study.","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"R28-6-20210203","first-page":"257","article-title":"Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia.","volume":"2","author":"Martyre","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon \u03b1 in the treatment of polycythemia vera.","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-\u03b1.","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon \u03b1-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"R32-6-20210203","first-page":"1281","article-title":"Limited effects on JAK2 mutational status after pegylated interferon \u03b1-2b therapy in polycythemia vera and essential thrombocythemia.","volume":"91","author":"Samuelsson","year":"2006","journal-title":"Haematologica"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long term efficacy, safety and leukemogenic potential in myeloproliferative diseases.","volume":"5","author":"Fruchtman","year":"2005","journal-title":"Leuk Res"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia.","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an International Working Group.","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"issue":"suppl 1","key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-\u03b1 in the treatment of essential thrombocythemia.","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG101209, a selective JAK2 kinase inhibitor, suppresses endogenous and cytokine-supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K\/L mutations.","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"762a","DOI":"10.1182\/blood.V108.11.2696.2696","article-title":"Efficacy of tyrosine kinase inhibitors in polycythemia vera.","volume":"108","author":"Gaikwad","year":"2006","journal-title":"Blood"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"1038a","DOI":"10.1182\/blood.V108.11.3632.3632","article-title":"JAK2 inhibitors for the treatment of myeloproliferative disorders.","volume":"108","author":"Hood","year":"2006","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0b013e3181594774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:39:10Z","timestamp":1786034350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-200711000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e3181594774","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}